User:Mr. Ibrahem/Casirivimab/imdevimab

Casirivimab/imdevimab, sold under the brand name REGEN-COV among others, is a medication used to treat and prevent COVID-19. As treatment it is used in mild to moderate disease in those at high risk. It works much less well in those with the Omicron variant. It is given by injection under the skin or into a vein.

Common side effects include infusion reaction and redness at the site of injection. Other side effects may include anaphylaxis, fever, and breathing problems. While it may be used in pregnancy, safety is unclear. It is two monoclonal antibodies, casirivimab (REGN10933) and imdevimab (REGN10987) which bind to the virus.

The combination is available under an emergency use authorization in the United States as of 2021. It is approved for medical use in Australia, the UK, and Japan. In the United States the government has purchased doses at 2,100 USD each, which they provide free. In Germany it was purchased for about €2,000 per dose.